Table 2 Clinical trials comparing volatile anesthetics with propofol in breast cancer surgery
From: Effect of Propofol on breast Cancer cell, the immune system, and patient outcome
Type of Study | Reference | Cancer | Surgery Type | Anesthetic Technique | Number of Patients | Outcome (95% CI) | Estimated Completion Date |
|---|---|---|---|---|---|---|---|
Retrospective | Enlund et al. | Breast Cancer | Breast cancer surgery | GA with propofol or sevoflurane | 1873 (620 in propofol and 1217 in sevoflurane) | 3% higher for overall survival at one year in propofol group (p < 0.001) | Finished |
Retrospective | Lee et al | Breast Cancer | Modified radical mastectomy | Propofol-based TIVA or sevoflurane-based anesthesia | 325 (173 in TIVA and 152 in sevoflurane) | Propofol group showed a lower rate of cancer recurrence (p = 0.037) | Finished |
Retrospective | Kim et al | Breast Cancer | Breast Cancer surgery | Propofol-based TIVA or sevoflurane-based anesthesia | 2645 (56 in TIVA and 2589 in volatile--base anesthesia) | No difference | Finished |
Prospective | University of Zurich | Breast Cancer | Breast Cancer surgery | GA with propofol TCI or sevoflurane | 231 | Circulating tumor cells at 3Â days after surgery | August, 2017 |
Prospective | Konkuk University Medical Center | Breast Cancer | Breast Cancer surgery | GA with propofol or sevoflurane | 300 | NK cell activity at 1 and 24Â h after surgery | July, 2020 |
Prospective | Uppsala University | Breast, colonic and rectal cancer | Breast Cancer surgery | GA with propofol or sevoflurane | 2000 | Overall 5-year survival | December, 2022 |